Azenta, Inc. (AZTA)

In April 2026, Azenta appointed Trey Martin as President of its Multiomics business. In March 2026, the company acquired UK Biocentre Limited, and its stock price fell to new lows around $20, while also divesting its B Medical Systems business. In February 2026, Azenta reported Q1 fiscal year 2026 earnings, missing EPS forecasts but surpassing revenue expectations, and announced a partnership with Frontier Space. In January 2026, Evercore ISI Group upgraded Azenta's stock. In December 2025, Zacks highlighted Azenta as a "Bear of the Day." In November 2025, Azenta reported its Q4 and full-year fiscal 2025 results, with revenue for the full year up 4% and organic revenue increasing by 3%.

While specific statements about demand seasonality for Azenta's direct products and services are not readily available, the broader life sciences and pharmaceutical industries it serves can experience some cyclical patterns. Demand for life sciences solutions can be influenced by factors such as fiscal calendars, regulatory changes and clinical/commercial timing. However, the underlying demand for multiomics services and automated sample storage systems is generally driven by long-term trends, suggesting a more consistent growth trajectory rather than sharp seasonal fluctuations for its core offerings.

Azenta, Inc. is a global provider of life sciences solutions, specializing in sample management and multiomics services, operating within the Healthcare sector. Its core business revolves around enabling faster breakthroughs and therapies in the life sciences. Major products and services include automated cold storage solutions, sample management solutions, multiomics services under the GENEWIZ brand, and biorepository services. Key brands include GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta maintains a global presence with operations and facilities across North America, Europe, and Asia. Its corporate headquarters are located in Burlington, Massachusetts, USA, with specific locations including Waltham, Indianapolis, and La Jolla in the USA, and Suzhou in China. The company also expanded its biorepository capabilities in the UK through the acquisition of UK Biocentre Limited.

Azenta is perceived as a premium provider in the life sciences industry, commanding a price premium due to its global scale and ISO-quality certifications. The company actively engages in ESG initiatives, publishing a 2024 ESG Report that highlighted achievements such as a 20% reduction in Scope 1 & 2 Greenhouse Gas emissions, advancements in sustainable innovation with products like the BioArc™ Ultra, and the launch of an LGBTQIA+ Employee Resource Group.

Institutional investors hold a significant portion of Azenta's stock, above 98% as of Q1 2025. Major institutional owners include BlackRock, Inc., Politan Capital Management LP, Vanguard Group Inc, Dimensional Fund Advisors Lp, Millennium Management Llc, State Street Corp, GW&K Investment Management, LLC, Allspring Global Investments Holdings, LLC, Conestoga Capital Advisors, LLC, and Congress Asset Management Co /ma. Nierenberg Investment Management Company Inc is a significant individual shareholder, and insiders hold approximately 10.90% of the stock.